Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites

NCT01457495 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01457495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01457495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
September 30, 1998
Completion date
September 30, 1999
Enrollment
312 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b (hib), hepatitis b, pertussis, poliomyelitis, tetanus